Share on StockTwits

Shares of InterMune (NASDAQ:ITMN) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 9,575,169 shares, a decline of 16.4% from the July 15th total of 11,458,044 shares, AnalystRatingsNetwork reports. Based on an average trading volume of 1,796,186 shares, the days-to-cover ratio is currently 5.3 days. Approximately 9.9% of the company’s shares are sold short.

In other InterMune news, CEO Daniel G. Welch unloaded 171,025 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $44.98, for a total transaction of $7,692,704.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on ITMN. Analysts at William Blair raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Friday, August 8th. Separately, analysts at Stifel Nicolaus raised their price target on shares of InterMune from $51.00 to $53.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. Finally, analysts at Robert W. Baird raised their price target on shares of InterMune from $44.00 to $50.00 in a research note on Thursday, August 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. InterMune presently has an average rating of “Buy” and an average target price of $44.85.

Shares of InterMune (NASDAQ:ITMN) opened at 45.49 on Wednesday. InterMune has a 52-week low of $10.95 and a 52-week high of $47.72. The stock has a 50-day moving average of $43.87 and a 200-day moving average of $34.23. The company’s market cap is $4.912 billion.

InterMune (NASDAQ:ITMN) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.72) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter last year, the company posted ($0.77) earnings per share. InterMune’s revenue was up 141.2% compared to the same quarter last year. On average, analysts predict that InterMune will post $-2.73 earnings per share for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Receive News & Ratings for InterMune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterMune Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.